NCT01419041 - A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Renal Impairment

Interventions

DRUG

crizotinib

Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min)

DRUG

crizotinib

Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)

Trial Locations (3)

Pfizer Investigational Site, DeLand

Pfizer Investigational Site, Saint Paul

Pfizer Investigational Site, Anaheim